Systematic immunology of tuberculosis,a critical step in the global war against tuberculosis disease

doi:10.19983/j.issn.2096-8493.20230073

Journal of Tuberculosis and Lung Disease ›› 2023, Vol. 4 ›› Issue (4): 261-271.doi: 10.19983/j.issn.2096-8493.20230073

• Special Articles • Next Articles

Systematic immunology of tuberculosis,a critical step in the global war against tuberculosis disease

Zhu Guofeng¹(), Yu Weiye²(), Wang Yuan³(), Liu Xiaoqing⁴(), Gao Qian⁵(), Li Liang⁶(), Lu Hongzhou¹()

¹National Clinical Research Center for Infectious Diseases/The Third People’s Hospital of Shenzhen, Shenzhen 518112, China
²Shenzhen Municipal Health Economics Association, Shenzhen 518020,China
³Department of National Science and Technology Major Project,Ministry of Science and Technology,Beijing 100862,China
⁴Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
⁵Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China
⁶Beijing Chest Hospital, Capital Medical University, Beijing 101149, China

Received:2023-06-16 Online:2023-08-20 Published:2023-08-15
Contact: Zhu Guofeng, Email: zhugf2014@126.com; Yu Weiye, Email: ywy2202@126.com; Wang Yuan, Email: 41824660@qq.com; Liu Xiaoqing, Email: liuxq@pumch.cn; Gao Qian, Email: qiangao@fudan.edu.cn; Li Liang, Email: liliang69@vip.sina.com; Lu Hongzhou, Email: luhongzhou@fudan.edu.cn

Abstract

Abstract:

A new era of novel vaccine and drug development against tuberculosis disease arrived with the failed clinical trial of MVA85A published in 2013. The breakthrough of systematic immunology of tuberculosis, which is the most critical challenge in developing novel technologies and products to end tuberculosis, is leading the reconstruction of the feature and position of strength of all countries in the ongoing struggle of global tuberculosis control.

Key words: Tuberculosis, Immunologic techniques, Disease models, animal, Vaccines, Systematic immunology

CLC Number:

Zhu Guofeng, Yu Weiye, Wang Yuan, Liu Xiaoqing, Gao Qian, Li Liang, Lu Hongzhou. Systematic immunology of tuberculosis,a critical step in the global war against tuberculosis disease[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(4): 261-271. doi: 10.19983/j.issn.2096-8493.20230073

Figures/Tables 1

References 12

[1]	World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance[EB/OL]. 2020-01-28. [2023-04-16]. https://apps.who.int/iris/handle/10665/330893.
[2]	朱国峰, 刘晓清. 结核病比较免疫学时代的机遇和挑战. 结核与肺部疾病杂志, 2020, 1(3):195-212. doi:10.3969/j.issn.2096-8493.2020.03.002. doi: 10.3969/j.issn.2096-8493.2020.03.002
[3]	World Health Organization. Global Tuberculosis Reports 2022. Geneva: World Health Organization, 2022.
[4]	The Nobel Prize in Chemistry 1993. NobelPrize.org[EB/OL]. [2022-02-16]. https://www.nobelprize.org/prizes/%20chemistry/1993/summary.
[5]	Cole ST, Brosch R, Parkhil Jl, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393(6685):537-554. doi:10.1038/31159. doi: 10.1038/31159
[6]	Bardarov S, Bardarov S, Pavelka MS, et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M.bovis BCG and M.smegmatis. Microbiology (Reading), 2002, 148(Pt 10):3007-3017. doi:10.1099/00221287-148-10-3007. doi: 10.1099/00221287-148-10-3007 URL
[7]	Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine,in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, 2013, 381:1021-1028. doi:10.1016/S0140-6736(13)60177-4. doi: 10.1016/S0140-6736(13)60177-4 URL
[8]	Deng J, Bi L, Zhou L, et al. 2014 Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity. Cell Rep, 2014, 9(6):2317-2329. doi:10.1016/j.celrep.2014.11.023. doi: 10.1016/j.celrep.2014.11.023 URL
[9]	Davies DH, Liang X, Hernandez JE, et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A, 2005, 102(3):547-552. doi:10.1073/pnas.0408782102. doi: 10.1073/pnas.0408782102 URL
[10]	Gideon HP, Phuah JY, Myers AJ, et al. Variability in Tuberculosis Granuloma T Cell Responses Exists, but a Balance of Pro- and Anti-inflammatory Cytokines Is Associated with Steri-lization. Plos Pathogen, 2015, 11(1):e1004603. doi:10.1371/journal.ppat.1004603. doi: 10.1371/journal.ppat.1004603 URL
[11]	Mothé BR, Lindestam Arlehamn CS, Dow C, et al. The TB-specific CD4⁺ T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis (Edinb), 2015, 95(6):722-735. doi:10.1016/j.tube.2015.07.005. doi: 10.1016/j.tube.2015.07.005 URL
[12]	习近平. 放眼世界,我们面对的是百年未有之大变局[EB/OL]. [2017-12-29]. https://baijiahao.baidu.com/s?id=1588086197016249556&wfr=spider&for=pc.

编号	名称	策略内容	依托单元	单元策略核心	技术目标目的	总体目的和特征
1	一举	高举“结核病比较免疫学”高科技大旗	结核病比较免疫学中心	行结核分枝杆菌突变体文库构建之劳备全球最强全系列动物P3实验之力领全球结核病比较免疫学迭代发展赢全球新疫苗、新药物竞争	支撑全球的MTB分子遗传、免疫学技术平台规模完善的全球领先水平P3动物模型实力全球结核病比较免疫学领域率先突破新技术时代创新药物和疫苗研发科创高地	目的:实现全球领先的技术话语权,成为传染病免疫学领域学术高度和应用价值的定位尺度特征:科创引领实力+经济
2	一占	一占“结核病临床负担转型”机遇	结核病临床试验中心	借结核病比较免疫学高科技之机乘国家临床中心资源鼓荡之风成结核病药物、疫苗临床评价之实	组织规范临床结核病样本资源进行国际水平药物临床评价进行国际水平疫苗临床评价	目的:国际标准结核病临床试验评价,形成结核病转化医学CRO平台特征:经济+临床资源支撑
3	一占	一占“国家卫生发展策略需要”先机	WHO跨国结核病中国区域依托参比实验室	用区域实验室日常内外联通的务实机制推国内外双向政策技术转化的公共卫生路线着力于成为参比技术评价的全球集成权威	把握全球一体化传染病防控发展趋势主动融合国内外公共卫生领域深度交流开放的需要形成参与并主导WHO结核病业务的战略根基	目的:内外主动地了解趋势并清晰立场,形成全球公共卫生事业新格局特征:经济+政治政策影响

[1]	Gong Yabo, Liu Liqin, Xu Zuhui, Yang Yuan. Study on impact of COVID-19 on medical services of tuberculosis designated hospitals in Hunan Province [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 277-282.
[2]	Peng Xiangdong, Xu Yaoyao, Hu Xiaojiang, Guo Lijun, Bo Jia. Analysis of the status and effects of the public-funded free 23-valent pneumococcal polysaccharide vaccination among elderly aged 60 years or older in Shanghai, 2013—2023 [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 283-294.
[3]	Song Yiyan, Ma Liling, Chen Hui, Hang Yin, Chen Sufang, Xu Junchi, Wu Minjuan, Xu Ping. Value of interferon-γ release assays in the diagnosis of tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 313-317.
[4]	Jiang Jun, Li Yun, Jiang Wei, Zhang Xiaolong. Analysis of latent tuberculosis infection and related factors in close contacts of pulmonary tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 318-322.
[5]	Zhang Yuhua. Epidemiological characteristics of pulmonary tuberculosis patients in central urban area of Tianjin City from 2011 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 323-327.
[6]	Wang Weibing, Li Na, Hao Jing, Jing Rui. An investigation on a cluster of pulmonary tuberculosis in an off-campus study room [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 328-333.
[7]	Zhou Lin, Liu Eryong, Zhao Yanlin. Select appropriate treatment plan and correctly evaluate the efficacy of anti-tuberculosis treatment, improving the treatment quality of rifampicin sensitive tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 189-193.
[8]	Gao Wenwan, Guo Jianqiong, Li Tongxin, Han Mei, Yan Xiaofeng, Yang Song, Tang Shenjie. The interpretation of the key points of the Expert Consensus on Immunotherapy for Tuberculosis (2022 edition) [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 194-197.
[9]	Ye Jiang’e, Wang Jingqiu, Wang Jian, Sang Yingying. The effect of patient care and support management model on the self-discipline and self-efficacy of tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 216-222.
[10]	Lu Qinbao, Wu Haocheng, Ding Zheyuan, Fu Tianying, Wu Chen, Lin Junfen. Analysis on effect of automatic early warning of pulmonary tuberculosis cases in schools in Zhejiang Province [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 223-228.
[11]	Liu Liqin, Ming Hui, Xu Zuhui. Study on the influence of COVID-19 epidemic on the work of tuberculosis prevention and control institutions in Hunan Province [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 229-234.
[12]	Ge Qiping, Gao Mengqiu. Attach importance to the differential diagnosis of abnormal liver function in tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 110-114.
[13]	Zhong Miner, Du Yuhua, Zhang Danni, Lin Ying, Wu Guifeng, Wang Ting, Liu Jianxiong. Analysis of latent tuberculosis infection among middle school and university freshmen in Guangzhou from 2018 to 2021 [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 115-119.
[14]	Zhou Jianwei, Zhang Songtao, Li Zhanhui, Xu Xingjun, Zhang Wei, Zhao Hongxia. Baseline screening and follow-up cohort study of close contacts of school tuberculosis epidemic [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 120-127.
[15]	Yang Chao, Wang Jing, Xie Ke, Tang Guilin, Gao Hanqing, Wang Bin. Analysis of the epidemiological characteristics and treatment outcomes of pulmonary tuberculosis with positive etiology in Tongzhou, Beijing from 2012 to 2021 [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 128-134.

Systematic immunology of tuberculosis,a critical step in the global war against tuberculosis disease

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 12

Related Articles 15

Recommended Articles

Metrics

Comments